FDA Approves First Muscle-Targeted Therapy for SMA

A new chapter in spinal muscular atrophy treatment opened this month when the FDA approved Isembyld, the first therapy designed specifically to improve muscle function in people living with SMA. For families like Amanda Stanton's, whose son Dash has SMA, the news brings real hope for stronger, more independent lives.

Spinal muscular atrophy is a leading genetic cause of death in infants and affects muscle strength throughout life. The disease often requires lifelong support for mobility, breathing, and daily activities, making each new treatment breakthrough deeply personal for thousands of families.

Isembyld works differently than existing SMA medications. While current treatments focus on the genetic cause of the disease, this new monthly infusion targets the muscles themselves, helping them grow stronger even while patients continue their regular therapy.

The approval builds on decades of scientific work, including research by Dr. Se-Jin Lee at the University of Connecticut, whose early studies on muscle growth became the foundation for this treatment. The Muscular Dystrophy Association invested over $50 million in SMA research alone, helping pave the way for this milestone.

Clinical trials showed meaningful improvements in motor function for people with SMA. The pivotal SAPPHIRE study demonstrated that patients could maintain and even improve their ability to move, offering something families have long hoped for: not just slowing decline, but building strength.

The Ripple Effect

This approval represents more than one new treatment option. It signals a shift in how doctors approach SMA care, moving from simply slowing disease progression to actively improving quality of life.

For children at MDA Summer Camp like Dash, stronger muscles mean more time doing what they love. For adults managing SMA, it means greater independence in daily tasks that many take for granted.

Dr. Randal Richardson, director of an MDA Care Center in Minnesota, calls it the beginning of a new era focused on improving function rather than just stopping decline. The therapy can work alongside existing treatments, giving doctors more tools to help their patients thrive.

The Muscular Dystrophy Association has funded research leading to nearly every approved therapy for neuromuscular diseases over the past 75 years. Their $1.2 billion investment in research has helped bring more than 30 FDA-approved treatments to market in the last decade alone.

Families can learn more about Isembyld through upcoming webinars in October hosted by Scholar Rock, the therapy's developer. The company plans separate sessions for families and clinicians to explain how the treatment works and who might benefit.

Amanda Stanton speaks for countless families when she describes what this means: "We want Dash to keep doing the things he loves without worrying that his muscles will stop keeping up with him."